|
Sustained Delivery of RhoA activator for Treatment of Intervertebral Disc Degeneration |
1R21AR080516-01 |
|
NIAMS |
2022 |
|
Investigating proteostasis in facioscapulohumeral muscular dystrophy |
1R21AR080887-01 |
|
NIAMS |
2022 |
|
Translational development of recombinant protein therapeutic for LGMD2B |
1R41AR081205-01 |
|
NIAMS |
2022 |
|
A novel agent for preventing fatty degeneration of muscles in LGMD2B |
1R43AR081168-01A1 |
|
NIAMS |
2022 |
|
Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD) |
1R43AR081195-01 |
|
NIAMS |
2022 |
|
X-ray Visualized Implanted Sensor for Prosthetic Joint Infection (X-VIS-PJI) |
1R43AR081748-01 |
|
NIAMS |
2022 |
|
CRISPR therapy in the canine DMD model |
1R56AR081544-01 |
|
NIAMS |
2022 |
|
Pathogenic Alterations of the 3D Epigenetic Landscape in Dystrophin-Deficient Skeletal Muscles and Reversal by Dystrophin Re-Expression |
2R01AR056712-11A1 |
|
NIAMS |
2022 |
|
OA Pathogenesis beyond Cartilage: A preclinical study of the sources of OA pain |
3R01AR071431-05S1 |
|
NIAMS |
2022 |
|
Supplement: Developing Nanomaterial Platform for Intra-Cartilage Delivery of RNA Therapeutics against Joint Diseases |
3R01AR072027-06S1 |
|
NIAMS |
2022 |